The historical rank and industry rank for ATAI Life Sciences NV's Equity-to-Asset or its related term are showing as below:
ATAI'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.81 Med: 0.85 Max: 0.95
Current: 0.83
During the past 5 years, the highest Equity to Asset Ratio of ATAI Life Sciences NV was 0.95. The lowest was 0.81. And the median was 0.85.
ATAI's Equity-to-Asset is ranked better than 72.48% of 1566
companies
in the Biotechnology industry
Industry Median: 0.66
vs ATAI: 0.83
ATAI Life Sciences NV Equity-to-Asset Historical Data
The historical data trend for ATAI Life Sciences NV's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ATAI Life Sciences NV's Equity-to-Asset
For the Biotechnology subindustry, ATAI Life Sciences NV's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ATAI Life Sciences NV's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ATAI Life Sciences NV's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where ATAI Life Sciences NV's Equity-to-Asset falls into.
ATAI Life Sciences NV Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
ATAI Life Sciences NV's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ATAI Life Sciences NV (NAS:ATAI) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
ATAI Life Sciences NV Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of ATAI Life Sciences NV's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
ATAI Life Sciences NV (ATAI Life Sciences NV) Business Description
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ATAI has been successfully added to your 